Metabolic Metabolic 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1 Safety CARMELINA study; CArdiovascular and Renal Microvascular outcomE study with LINAgliptin in patients with type 2 diabetes mellitus CAROLINA Study; CARdiovascular Outcome study of LINAgliptin vs glimepiride in patients with type 2 diabetes EMPRISE Study; Empagliflozin real world effectiveness & Safety EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D EMPRISE Study; Empagliflozin real world safety and reduction of acute kidney injury 02:49 CARMELINA Study Rational & Background Global Experts Video 03:31 CARMELINA Study at glance; Linagliptin reassured long-term CV & Kideny safety profile Global Experts Video 06:35 EMPRISE Study; Empagliflozin real world comparative effictiveness & safety Production date: Apr 2020
